Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market

Product Saw Zero Sales Since April Approval

 
• By Mandy Jackson
  
Beqvez was the last gene therapy left in Pfizer's portfolio (Shutterstock)

More from Strategy

More from Advanced Therapies